Superluminal Medicines vs McKesson

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (75 vs 79)
Superluminal Medicines logo

Superluminal Medicines

LeaderHealthcare

General

Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.

AI VisibilityBeta
Overall Score
B75
Category Rank
#78 of 596
AI Consensus
72%
Trend
stable
Per Platform
ChatGPT
76
Perplexity
80
Gemini
69

About

Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.

Full profile
McKesson logo

McKesson

LeaderHealthcare

General

Largest US pharmaceutical distributor with $308.9B FY2024 revenue; thin-margin distribution triopoly with Cencora and Cardinal Health; US Oncology Network (1,700+ oncologists) is highest-margin segment.

AI VisibilityBeta
Overall Score
B79
Category Rank
#26 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
82
Perplexity
76
Gemini
82

About

McKesson Corporation is the largest pharmaceutical distributor in North America and a leading healthcare services company, founded in 1833 in New York City by John McKesson and Charles Olcott and now headquartered in Irving, Texas, trading on NYSE (MCK). The company reported approximately $308.9 billion in revenues for fiscal year 2024 (ending March 31, 2024) under CEO Brian Tyler, making it one of the highest-revenue companies in the United States—though the vast majority of revenues represent pass-through pharmaceutical product costs distributed to approximately 40,000 pharmacies, health systems, and medical providers across North America. McKesson operates through four segments: U.S. Pharmaceutical (the dominant distribution engine), Prescription Technology Solutions (pharmacy benefits technology including CoverMyMeds e-prior authorization), Medical-Surgical Solutions (physician office and extended care medical supply distribution), and International (primarily Canadian distribution through McKesson Canada).

Full profile

AI Visibility Head-to-Head

75
Overall Score
79
#78
Category Rank
#26
72
AI Consensus
77
stable
Trend
stable
76
ChatGPT
82
80
Perplexity
76
69
Gemini
82
70
Claude
85
76
Grok
77

Key Details

Category
General
General
Tier
Leader
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.